Literature DB >> 19020900

Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q.

Hidetaka Yamamoto1, Taro Tobo, Mari Nakamori, Masakazu Imamura, Aya Kojima, Yoshinao Oda, Norimoto Nakamura, Tomonari Takahira, Takashi Yao, Masazumi Tsuneyoshi.   

Abstract

PURPOSE: Multiple gastrointestinal stromal tumors (GISTs) rarely occur in patients with neurofibromatosis type 1 (NF-1). In contrast to sporadic GISTs characterized by frequent allelic losses of 1p, 14q and 22q and mutations of KIT or PDGFRA gene with the activation of the downstream RAS-MAPK pathway, the molecular pathogenetic mechanisms of NF-1-related GISTs (NF-1 GISTs) remain unclear.
METHODS: Thirty-one GISTs and two foci of Cajal cell hyperplasia (CCH) were obtained from five patients with NF-1. Phospho-MAPK p44/42 expression was examined by immunohistochemical stain. KIT and PDGFRA mutations were analyzed by PCR and direct sequencing methods. Loss of heterozygosity (LOH) was analyzed by PCR-based method with microsatellite markers on 14q and 22q.
RESULTS: Immunohistochemical expression of phospho-MAPK p44/42 was frequently found in NF-1 GISTs (23/25 cases, 92%). Neither the KIT nor PDGFRA mutation was detected in 25 NF-1 GISTs and 2 CCH. Among the informative cases, LOH was seen at 14q and 22q in 7/8 (87.5%) and 5/12 (41.7%) NF-1 GISTs, respectively. Such LOH was not detected in CCH, whereas it was detected in small GIST less than 1 cm in diameter.
CONCLUSIONS: Our results support that KIT and PDGFRA mutations are very rare events in NF-1 GIST. Rather, activation of the Ras-MAPK pathway associated with the inactivation of the NF1 gene may play an important role in the cell proliferation of NF-1 GIST. Additionally, LOH at 14q and 22q may contribute to the relatively early phase of tumor development of NF-1 GIST.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19020900     DOI: 10.1007/s00432-008-0514-z

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  37 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors).

Authors:  J A Breiner; J Meis-Kindblom; L G Kindblom; E McComb; J Liu; M Nelson; J A Bridge
Journal:  Cancer Genet Cytogenet       Date:  2000-07-15

3.  Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

Authors:  Hans Prenen; Jan Cools; Nicole Mentens; Cedric Folens; Raf Sciot; Patrick Schöffski; Allan Van Oosterom; Peter Marynen; Maria Debiec-Rychter
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

4.  NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics.

Authors:  Johanna Andersson; Harri Sihto; Jeanne M Meis-Kindblom; Heikki Joensuu; Nina Nupponen; Lars-Gunnar Kindblom
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

5.  Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours.

Authors:  H Chen; S Hirota; K Isozaki; H Sun; A Ohashi; K Kinoshita; P O'Brien; L Kapusta; I Dardick; T Obayashi; T Okazaki; Y Shinomura; Y Matsuzawa; Y Kitamura
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

6.  Somatic mutations in the neurofibromatosis 1 gene in human tumors.

Authors:  Y Li; G Bollag; R Clark; J Stevens; L Conroy; D Fults; K Ward; E Friedman; W Samowitz; M Robertson
Journal:  Cell       Date:  1992-04-17       Impact factor: 41.582

7.  Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).

Authors:  Anette Duensing; Fabiola Medeiros; Bryna McConarty; Nora E Joseph; Dipak Panigrahy; Samuel Singer; Christopher D M Fletcher; George D Demetri; Jonathan A Fletcher
Journal:  Oncogene       Date:  2004-05-13       Impact factor: 9.867

Review 8.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

9.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

10.  Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo.

Authors:  D A Ingram; F C Yang; J B Travers; M J Wenning; K Hiatt; S New; A Hood; K Shannon; D A Williams; D W Clapp
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

View more
  19 in total

Review 1.  The genetic landscape of gastrointestinal stromal tumor lacking KIT and PDGFRA mutations.

Authors:  Sosipatros A Boikos; Constantine A Stratakis
Journal:  Endocrine       Date:  2014-07-16       Impact factor: 3.633

Review 2.  Gastrointestinal stromal tumours: origin and molecular oncology.

Authors:  Christopher L Corless; Christine M Barnett; Michael C Heinrich
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

3.  Preclinical model-based evaluation of Imatinib resistance induced by KIT mutations and its overcoming strategies in gastrointestinal stromal tumor (GIST).

Authors:  Qian Zhao; Cheng Zhang; Changsong Qi; Jing Yang; Yang Chen; Sai Ge; Lin Shen; Jing Gao; Jian Li
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

4.  Long segmental hyperplasia of interstitial cells of Cajal with giant diverticulum formation.

Authors:  Liyan Xue; Tian Qiu; Ying Song; Ling Shan; Xiuyun Liu; Lei Guo; Jianming Ying; Shuangmei Zou; Susheng Shi; Alexandros D Polydorides; Xinming Zhao; Ning Lu; Dongmei Lin
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

5.  Neurofibromatosis type 1 associated with pheochromocytoma and gastrointestinal stromal tumors: A case report and literature review.

Authors:  Dongfeng Pan; Peifeng Liang; Hongyan Xiao
Journal:  Oncol Lett       Date:  2016-06-01       Impact factor: 2.967

Review 6.  Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen's disease): clinicopathological spectrum with pathogenetic considerations.

Authors:  Abbas Agaimy; Nikolaos Vassos; Roland S Croner
Journal:  Int J Clin Exp Pathol       Date:  2012-10-20

7.  A case of pancreatic neuroendocrine tumor in a patient with neurofibromatosis-1.

Authors:  Takeshi Nishi; Yasunari Kawabata; Youko Hari; Hiroshi Imaoka; Noriyoshi Ishikawa; Seiji Yano; Riruke Maruyama; Yoshitsugu Tajima
Journal:  World J Surg Oncol       Date:  2012-07-23       Impact factor: 2.754

Review 8.  Gastrointestinal stromal tumors associated with neurofibromatosis 1: a single centre experience and systematic review of the literature including 252 cases.

Authors:  Pier Federico Salvi; Laura Lorenzon; Salvatore Caterino; Laura Antolino; Maria Serena Antonelli; Genoveffa Balducci
Journal:  Int J Surg Oncol       Date:  2013-12-09

Review 9.  Mesenchymal tumours of the gastrointestinal tract.

Authors:  Marta Sbaraglia; Gianluca Businello; Elena Bellan; Matteo Fassan; Angelo Paolo Dei Tos
Journal:  Pathologica       Date:  2021-06

10.  Diagnostic criteria, specific mutations, and genetic predisposition in gastrointestinal stromal tumors.

Authors:  Jean-Baptiste Bachet; Jean-François Emile
Journal:  Appl Clin Genet       Date:  2010-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.